An Interview with Stephanie Planque of Covalent Bioscience

Covalent Bioscience develops catalytic antibodies, a way to bind and neutralize target molecules in the body without consuming the antibody molecule itself. A given dose of catalytic antibody can thus remove many times more target molecules than is the case for standard monoclonal antibodies. This offers the potential for highly efficient removal of age-related amyloids present outside cells, perhaps the most interesting of the many possible use cases, such as those related to suppression of specific signal molecules. Like most biotech companies, the backstory behind the science emphasizes the point that progression of any given technology from academia to industry is slow indeed. Covalent Bioscience was incorporated in 2010 by Dr Sudhir Paul and Dr Richard Massey based on catalytic antibody technology and several exciting potential products for unmet medical needs. The technology and potential products were developed in Dr. Sudhir Paul's group at the University of Texas (UT). Dr Richard Massey and Dr Sudhir Paul have worked together on the field of catalytic antibody (or catabody) when Dr Massey was in Igen in the late 80s. I have worked with Dr. Paul since 1999 and am one of the co-founders of Covalent Bioscience. We, the founders of Covalent Bioscience, share the same conviction that our platform technology holds the potential to generate superior immunotherapeutic drugs and vaccines. Today, Covalent Bioscience has grown to a preclinical stage company holdi...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs